Eradivir Series A funding round (IMAGE)

Purdue University

Eradivir Series A funding round

Caption

Two Eradivir employees conduct research on the company’s EV25 influenza therapeutic. Eradivir, a preclinical biotech company, has completed a $10.25 million Series A funding round.

Credit

(Eradivir photo/Gregory Eakins)

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.